Traditional Chinese medicine for treating lung cancer

Abstract

The invention relates to the field of traditional Chinese medicine formulas and particularly relates to a traditional Chinese medicine for treating lung cancer. The traditional Chinese medicine is characterized by being prepared from the following raw material medicines in parts by weight: 15-20 parts of fructus akebiae, 10-15 parts of bock greenbrier rhizome, 8-12 parts of scolopendra, 10-12 parts of semen strychni, 10-15 parts of radix cynanchi paniculati, 6-10 parts of herba andrographis, 20-25 parts of herba rabdosiae, 6-8 parts of herba agrimoniae, 10-12 parts of exocarpium citri grandis, 12-15 parts of campylandra chinensis, 15-20 parts of psilotum nudum, 8-10 parts of ground beeltle, 12-16 parts of root and bark of ceylon houndstongue, 6-10 parts of root of kirilow rhodiola, 15-20 parts of semen lepidii, 16-18 parts of radix semiaquilegiae, 12-16 parts of cyrtomium rhizome, 3-5 parts of snakegourd fruit and 3-5 parts of rhizoma paridis, wherein scolopendra and ground beeltle are independently dried and ground into fine powder, the rest 17 raw material medicines are soaked in water and are decocted, filtrate is obtained after residues are removed, and the fine powder of scolopendra and ground beeltle is added into the filtrate, and the filtrate is uniformly stirred.

Description

technical field [0001] The invention relates to a Chinese patent medicine preparation, in particular to a traditional Chinese medicine for treating lung cancer. Background technique [0002] As we all know, the World Health Organization survey reports that in many countries and regions, the incidence of lung cancer accounts for the first place among malignant tumors. The vast majority of lung cancer originates from the bronchial mucosal epithelium, so it is called bronchial lung cancer. Lung cancer is what it is called for short or commonly. Surgical resection is the first choice for the treatment of lung cancer. The 5-year survival rate after surgery can reach more than 50% when the primary cancer is confined to the bronchopulmonary without distant metastasis and lymph node metastasis. However, most patients are already inoperable advanced patients when they are detected, and generally only radiotherapy and chemotherapy can be used for treatment. Currently commonly used...

AI Technical Summary

Problems solved by technology

The median survival period of targeted therapy drugs such as gefitinib is 5.4-18 months, most of which are concentrated in 9 months. The cost of chemotherapy is high, and targeted drugs are prone to drug resistance

Images